ALLO Allogene Therapeutics, Inc.

NASDAQ
$0.67

Allogene Therapeutics, Inc. (ALLO) Earnings News

Earnings press releases, previews and reviews for Allogene Therapeutics, Inc. (ALLO), newest first. Our most recent is review: Allogene Misses on a Wider Loss as ALPHA3 Enrollment Accelerates but Interim-Data Expectations Cool.